Agenus Inc (AGEN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Agenus Inc (AGEN) has a cash flow conversion efficiency ratio of 0.158x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-35.95 Million) by net assets ($-227.98 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Agenus Inc balance sheet independence to measure how much of total assets are equity-financed.
Agenus Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Agenus Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Agenus Inc to evaluate the quality of earnings relative to operating cash generation.
Agenus Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Agenus Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
NIIT Limited
NSE:NIITLTD
|
-0.015x |
|
TRUFIN PLC
F:29U
|
N/A |
|
Den Networks Limited
NSE:DEN
|
0.015x |
|
Waton Financial Limited Ordinary Shares
NASDAQ:WTF
|
0.105x |
|
STLLR Gold Inc.
TO:STLR
|
-0.045x |
|
Zapata Computing Holdings Inc. Common Stock
NASDAQ:ZPTA
|
0.032x |
|
HIM International Music
TWO:8446
|
0.069x |
|
Avita Medical Inc
AU:AVH
|
0.411x |
Annual Cash Flow Conversion Efficiency for Agenus Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Agenus Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Agenus Inc worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-277.86 Million | $-158.31 Million | 0.570x | +10.28% |
| 2024-12-31 | $-306.42 Million | $-158.31 Million | 0.517x | -65.81% |
| 2023-12-31 | $-148.38 Million | $-224.20 Million | 1.511x | -52.70% |
| 2022-12-31 | $-54.90 Million | $-175.37 Million | 3.194x | +1408.48% |
| 2021-12-31 | $47.91 Million | $10.14 Million | 0.212x | -67.80% |
| 2020-12-31 | $-211.50 Million | $-139.10 Million | 0.658x | +714.39% |
| 2019-12-31 | $-231.34 Million | $-18.68 Million | 0.081x | -89.25% |
| 2018-12-31 | $-174.55 Million | $-131.09 Million | 0.751x | -39.57% |
| 2017-12-31 | $-75.82 Million | $-94.23 Million | 1.243x | -39.19% |
| 2016-12-31 | $-39.13 Million | $-79.96 Million | 2.044x | +406.40% |
| 2015-12-31 | $70.73 Million | $-47.18 Million | -0.667x | +59.85% |
| 2014-12-31 | $23.02 Million | $-38.23 Million | -1.661x | -138.11% |
| 2013-12-31 | $-4.48 Million | $-19.53 Million | 4.359x | +5274.33% |
| 2012-12-31 | $-12.02 Million | $1.01 Million | -0.084x | -110.80% |
| 2011-12-31 | $-20.83 Million | $-16.25 Million | 0.780x | -22.26% |
| 2010-12-31 | $-14.71 Million | $-14.76 Million | 1.003x | -29.59% |
| 2009-12-31 | $-16.98 Million | $-24.19 Million | 1.425x | +17.91% |
| 2008-12-31 | $-23.92 Million | $-28.91 Million | 1.209x | +113.12% |
| 2007-12-31 | $-47.06 Million | $-26.69 Million | 0.567x | -78.05% |
| 2006-12-31 | $-17.39 Million | $-44.94 Million | 2.584x | +224.26% |
| 2005-12-31 | $31.90 Million | $-66.33 Million | -2.079x | -267.49% |
| 2004-12-31 | $106.44 Million | $-60.22 Million | -0.566x | -16.33% |
| 2003-12-31 | $105.25 Million | $-51.19 Million | -0.486x | +25.60% |
| 2002-12-31 | $77.76 Million | $-50.83 Million | -0.654x | -34.79% |
| 2001-12-31 | $75.92 Million | $-36.83 Million | -0.485x | -274.02% |
| 2000-12-31 | $116.70 Million | $-15.13 Million | -0.130x | +50.34% |
| 1999-12-31 | $51.70 Million | $-13.50 Million | -0.261x | -- |
About Agenus Inc
Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvan… Read more